|
1
|
Dumstrei K, Chen H and Brenner H: A
systematic review of serum autoantibodies as biomarkers for
pancreatic cancer detection. Oncotarget. 7:11151–11164. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Klompmaker S, de Rooij T, Korteweg JJ, van
Dieren S, van Lienden KP, van Gulik TM, Busch OR and Besselink MG:
Systematic review of outcomes after distal pancreatectomy with
coeliac axis resection for locally advanced pancreatic cancer. Br J
Surg. 103:941–949. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paiella S, Sandini M, Gianotti L,
Butturini G, Salvia R and Bassi C: The prognostic impact of
para-aortic lymph node metastasis in pancreatic cancer: A
systematic review and meta-analysis. Eur J Surg Oncol. 42:616–624.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Subramani R, Gangwani L, Nandy SB,
Arumugam A, Chattopadhyay M and Lakshmanaswamy R: Emerging roles of
microRNAs in pancreatic cancer diagnosis, therapy and prognosis
(Review). Int J Oncol. 47:1203–1210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang J, Li J, Zhu R, Zhang H, Zheng Y, Dai
W, Wang F, Shen M, Chen K, Cheng P, et al: K-ras mutational status
in cytohistological tissue as a molecular marker for the diagnosis
of pancreatic cancer: A systematic review and meta-analysis. Dis
Markers. 2014:5737832014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spadavecchia J, Movia D, Moore C, Maguire
CM, Moustaoui H, Casale S, Volkov Y and Prina-Mello A: Targeted
polyethylene glycol gold nanoparticles for the treatment of
pancreatic cancer: From synthesis to proof-of-concept in vitro
studies. Int J Nanomedicine. 11:791–822. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldsmith C, Price P, Cross T, Loughlin S,
Cowley I and Plowman N: Dose-volume histogram analysis of
stereotactic body radiotherapy treatment of pancreatic cancer: A
focus on duodenal dose constraints. Semin Radiat Oncol. 26:149–156.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Spadi R, Brusa F, Ponzetti A, Chiappino I,
Birocco N, Ciuffreda L and Satolli MA: Current therapeutic
strategies for advanced pancreatic cancer: A review for clinicians.
World J Clin Oncol. 7:27–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang K, Lu W, Qin W and Wu Y: Neoadjuvant
therapy for patients with borderline resectable pancreatic cancer:
A systematic review and meta-analysis of response and resection
percentages. Pancreatology. 16:28–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Blogowski W, Bodnarczuk T and Starzynska
T: Concise review: Pancreatic cancer and bone marrow-derived stem
cells. Stem Cells Transl Med. 5:938–945. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miyoshi N, Wagatsuma H, Wakana S,
Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino
T and Ishino F: Identification of an imprinted gene, Meg3/Gtl2 and
its human homologue MEG3, first mapped on mouse distal chromosome
12 and human chromosome 14q. Genes Cells. 5:211–220. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oczkowicz M, Ropka-Molik K, Piorkowska K,
Rozycki M and Rejduch B: Frequency of DLK1 c.639C>T polymorphism
and the analysis of MEG3/DLK1/PEG11 cluster expression in muscle of
swine raised in Poland. Meat Sci. 88:627–630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Benetatos L, Vartholomatos G and
Hatzimichael E: MEG3 imprinted gene contribution in tumorigenesis.
Int J Cancer. 129:773–779. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kagami M, O'Sullivan MJ, Green AJ, Watabe
Y, Arisaka O, Masawa N, Matsuoka K, Fukami M, Matsubara K, Kato F,
et al: The IG-DMR and the MEG3-DMR at human chromosome 14q32.2:
Hierarchical interaction and distinct functional properties as
imprinting control centers. PLoS Genet. 6:e10009922010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Rice K, Wang Y, Chen W, Zhong Y,
Nakayama Y, Zhou Y and Klibanski A: Maternally expressed gene 3
(MEG3) noncoding ribonucleic acid: Isoform structure, expression,
and functions. Endocrinology. 151:939–947. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang X, Zhou Y, Mehta KR, Danila DC,
Scolavino S, Johnson SR and Klibanski A: A pituitary-derived MEG3
isoform functions as a growth suppressor in tumor cells. J Clin
Endocrinol Metab. 88:5119–5126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chunharojrith P, Nakayama Y, Jiang X, Kery
RE, Ma J, De La Hoz, Ulloa CS, Zhang X, Zhou Y and Klibanski A:
Tumor suppression by MEG3 lncRNA in a human pituitary tumor derived
cell line. Mol Cell Endocrinol. 416:27–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv J, Qiu M, Xia W, Liu C, Xu Y, Wang J,
Leng X, Huang S, Zhu R, Zhao M, et al: High expression of long
non-coding RNA SBF2-AS1 promotes proliferation in non-small cell
lung cancer. J Exp Clin Cancer Res. 35:752016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Costales MG, Rzuczek SG and Disney MD:
Comparison of small molecules and oligonucleotides that target a
toxic, non-coding RNA. Bioorg Med Chem Lett. 26:2605–2609. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Victoria Martinez B, Dhahbi JM, Nunez
Lopez YO, Lamperska K, Golusinski P, Luczewski L, Kolenda T, Atamna
H, Spindler SR, Golusinski W and Masternak MM: Circulating small
non-coding RNA signature in head and neck squamous cell carcinoma.
Oncotarget. 6:19246–19263. 2015.PubMed/NCBI
|
|
21
|
Nowacki FC, Swain MT, Klychnikov OI, Niazi
U, Ivens A, Quintana JF, Hensbergen PJ, Hokke CH, Buck AH and
Hoffmann KF: Protein and small non-coding RNA-enriched
extracellular vesicles are released by the pathogenic blood fluke
Schistosoma mansoni. J Extracell Vesicles. 4:286652015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marchand V and Branlant C: Quantification
and quality control of a small non-coding RNA preparation. Methods
Mol Biol. 1296:17–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Marti E and Estivill X: Small non-coding
RNAs add complexity to the RNA pathogenic mechanisms in
trinucleotide repeat expansion diseases. Front Mol Neurosci.
6:452013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martens-Uzunova ES, Olvedy M and Jenster
G: Beyond microRNA-novel RNAs derived from small non-coding RNA and
their implication in cancer. Cancer Lett. 340:201–211. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Munagala R, Aqil F and Gupta RC: Exosomal
miRNAs as biomarkers of recurrent lung cancer. Tumour Biol.
37:10703–10714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dimitrova DI, Yang X, Reichenbach NL,
Karakasidis S, Sutton RE, Henderson EE, Rogers TJ and Suhadolnik
RJ: Lentivirus-mediated transduction of PKR into CD34(+)
hematopoietic stem cells inhibits HIV-1 replication in
differentiated T cell progeny. J Interferon Cytokine Res.
25:345–360. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yallop CA and Svendsen I: The effects of
G418 on the growth and metabolism of recombinant mammalian cell
lines. Cytotechnology. 35:101–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wai-Hoe L, Wing-Seng L, Ismail Z and
Lay-Harn G: SDS-PAGE-based quantitative assay for screening of
kidney stone disease. Biol Proced Online. 11:145–160. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seviour EG, Sehgal V, Lu Y, Luo Z, Moss T,
Zhang F, Hill SM, Liu W, Maiti SN, Cooper L, et al: Functional
proteomics identifies miRNAs to target a p27/Myc/phospho-Rb
signature in breast and ovarian cancer. Oncogene. 35:691–701. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Madhavan D, Peng C, Wallwiener M, Zucknick
M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, et
al: Circulating miRNAs with prognostic value in metastatic breast
cancer and for early detection of metastasis. Carcinogenesis.
37:461–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tian W, Liu J, Pei B, Wang X, Guo Y and
Yuan L: Identification of miRNAs and differentially expressed genes
in early phase non-small cell lung cancer. Oncol Rep. 35:2171–2176.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Endzelins E, Melne V, Kalnina Z,
Lietuvietis V, Riekstiņa U, Llorente A and Linē A: Diagnostic,
prognostic and predictive value of cell-free miRNAs in prostate
cancer: A systematic review. Mol Cancer. 15:412016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Masliah-Planchon J, Garinet S and Pasmant
E: RAS-MAPK pathway epigenetic activation in cancer: miRNAs in
action. Oncotarget. 7:38892–38907. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mathe A, Scott RJ and Avery-Kiejda KA:
MiRNAs and other epigenetic changes as biomarkers in triple
negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JC, Ahn S, Paik KH, Kim HW, Kang J,
Kim J and Hwang JH: Clinical impact of neoadjuvant treatment in
resectable pancreatic cancer: A systematic review and meta-analysis
protocol. BMJ Open. 6:e0104912016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kunk PR, Bauer TW, Slingluff CL and Rahma
OE: From bench to bedside a comprehensive review of pancreatic
cancer immunotherapy. J Immunother Cancer. 4:142016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kristensen A, Vagnildhaug OM, Gronberg BH,
Kaasa S, Laird B and Solheim TS: Does chemotherapy improve
health-related quality of life in advanced pancreatic cancer? A
systematic review. Crit Rev Oncol Hematol. 99:286–298. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Paiella S, Salvia R, Ramera M, Girelli R,
Frigerio I, Giardino A, Allegrini V and Bassi C: Local ablative
strategies for ductal pancreatic cancer (Radiofrequency Ablation,
Irreversible Electroporation): A review. Gastroenterol Res Pract.
2016:45083762016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gagliardi AR, Soong D and Gallinger S:
Identifying factors influencing pancreatic cancer management to
inform quality improvement efforts and future research: A scoping
systematic review. Pancreas. 45:161–166. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fan Y, Hu J, Feng B, Wang W, Yao G, Zhai J
and Li X: Increased risk of pancreatic cancer related to gallstones
and cholecystectomy: A systematic review and Meta-analysis.
Pancreas. 45:503–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stuopelyte K, Daniunaite K, Jankevicius F
and Jarmalaite S: Detection of miRNAs in urine of prostate cancer
patients. Medicina (Kaunas). 52:116–124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li HP, Huang HY, Lai YR, Huang JX, Chang
KP, Hsueh C and Chang YS: Silencing of miRNA-148a by
hypermethylation activates the integrin-mediated signaling pathway
in nasopharyngeal carcinoma. Oncotarget. 5:7610–7624. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu B, Shen ED, Liao MM, Hu YB, Wu K, Yang
P, Zhou L and Chen WD: Expression and mechanisms of long non-coding
RNA genes MEG3 and ANRIL in gallbladder cancer. Tumour Biol.
37:9875–9786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Luo G, Wang M, Wu X, Tao D, Xiao X, Wang
L, Min F, Zeng F and Jiang G: Long Non-coding RNA MEG3 inhibits
cell proliferation and induces apoptosis in prostate cancer. Cell
Physiol Biochem. 37:2209–2220. 2015. View Article : Google Scholar : PubMed/NCBI
|
